期刊
NATURE REVIEWS CANCER
卷 16, 期 8, 页码 525-537出版社
NATURE PORTFOLIO
DOI: 10.1038/nrc.2016.56
关键词
-
类别
资金
- Intramural Program of the Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
- Cancer Prevention Fellowship Program, National Cancer Institute, Rockville, Maryland, USA
Precision medicine relies on validated biomarkers with which to better classify patients by their probable disease risk, prognosis and/or response to treatment. Although affordable 'omics'-based technology has enabled faster identification of putative biomarkers, the validation of biomarkers is still stymied by low statistical power and poor reproducibility of results. This Review summarizes the successes and challenges of using different types of molecule as biomarkers, using lung cancer as a key illustrative example. Efforts at the national level of several countries to tie molecular measurement of samples to patient data via electronic medical records are the future of precision medicine research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据